Chimerix (CMRX) Set to Announce Quarterly Earnings

Chimerix (NASDAQ:CMRX) is expected to release its quarterly earnings report before the market opens on Thursday, November 7. Analysts forecast that the biopharmaceutical company will report a loss of $0.24 per share for the quarter.

The last earnings announcement from Chimerix was made on August 13, where the company reported a loss of $0.23 per share, aligning with analysts' expectations. During that quarter, Chimerix generated revenue of $0.13 million, which fell short of the anticipated $1.26 million. In comparison, the same quarter last year saw the company report losses of $0.21 per share. Looking forward, analysts predict that Chimerix will end the current fiscal year with an average loss of $1 per share and the same loss projected for the next fiscal year.

Chimerix Stock Performance

On Friday, Chimerix shares opened at $0.99. The company's 50-day and 200-day moving averages stand at $0.90 and $0.91, respectively. Chimerix has a market capitalization of $88.74 million and a price-to-earnings ratio of -1.04, with a beta of 1.12. Over the last twelve months, the stock has seen a low of $0.75 and a high of $1.30.

Analysts Provide New Price Targets

Recently, several analysts have issued their perspectives on Chimerix. Wedbush maintained an "outperform" rating with a price target of $6.00, while HC Wainwright reiterated a "buy" rating and set a price target of $11.00. Additionally, StockNews.com upgraded the stock from a "sell" rating to a "hold" rating.

About Chimerix

Chimerix, Inc. is focused on developing therapies aimed at improving and extending the lives of patients with serious diseases. Their product pipeline includes ONC201, which is currently in Phase 3 trials targeting H3 K27M-mutant diffuse glioma, along with ONC206, a treatment in Phase 1 trials for primary central nervous system tumors, focusing on pediatric and adult patients.

Chimerix, Earnings, Stock